4 innovative drugs have started large-scale clinical application, unveiling CMS’s first year of commercialization era of innovative drugs.
In 2023, CMS delivered quality innovation outcomes. Its three innovative drugs, Diazepam Nasal Spray (VALTOCO), Tildrakizumab Injection (ILUMETRI), Methotrexate Injection-psoriasis (METOJECT), have been included in the National Reimbursement Drug List (NRDL) after obtaining approvals of marketing in
In addition, in
The differentiated innovation pipeline stands as an important driver of the Company’s high-quality development. Driven by the twin-wheel of "Collaborative R&D and Independent R&D", CMS has continuously deployed global first-in-class (FIC) and best-in-class (BIC) innovative products guided by patient and clinical demands, and has enhanced its R&D capabilities of differentiated innovative products to empower the continuous transformation of scientific research outcomes into clinical application. As of now, CMS has deployed approximately 30 innovative products. Among them, 2 products, Methotrexate Injection - rheumatoid arthritis (RA) and Methylthioninium Chloride Enteric-coated Sustained-release Tablets, are currently under NDA review in
CMS states that innovation products expected to be continuously launched every year with higher efficiency and more controllable costs starting from 2023, continuing to energize the Company's mid- to long-term development. CMS is ready to embrace a brighter future full of opportunities.
Rooted in specialty therapeutical fields, empowering products to achieve clinical and commercial values
Commercialization capability is one of CMS’s core competitiveness. By continuously reinforcing and integrating its commercialization platform, the Company has further consolidated its specialty therapeutic fields focused operation system, and has promoted the independent operation of its three major business segments including cardio-cerebrovascular/gastroenterology, dermatology/medical aesthetics, and ophthalmology. Simultaneously, by leveraging upgraded compliance control system and supporting digital tools, CMS has continuously optimized its professional academic promotion capabilities guided by clinical evidence, and built a number of agile and efficient specialty therapeutical fields-focused commercialization teams.
The Dermatology and Medical Aesthetic Business "CMS Skinhealth" regards dermatology prescription products as its core, and extends to dermatology-grade skincare products and light medical aesthetic products, continually optimizing full lifecycle skin-health management solutions. CMS Skinhealth has officially initiated the promotion of ILUMETRI, relying on the accumulated academic platform of existing marketed products including Hirudoid (the repair agent for skin barrier with multiple functions) and Aethoxysklerol (a German original brand for the treatment of sclerotherapy of varicose veins with years of clinical application). Meanwhile, CMS Skinhealth has obtained the exclusive licenses for the commercialization of three regenerative medical aesthetic products, including Poly-L-lactic Acid Microparticle Filler Injection, Polycaprolactone Microsphere Gel for Injection and Calcium Hydroxylapatite Microsphere Gel for Injection, enriching its regenerative medical aesthetic product portfolio and enhancing the Company's competitiveness.
The Ophthalmology Business “CMS Vision” continues to improve its organizational structure and operating system, and actively promotes the identification, development and commercialization of urgently needed clinical solutions. Innovative medical device, EyeOP1 Glaucoma Treatment Device, has completed market access in many provinces and cities, and is synergized with the exclusive marketed product Augentropfen Stulln Mono Eye Drops in marketing and promotion. VEGFA/ANG2 Tetravalent Bispecific Antibody, a class I innovative biological agent, is under the phase I clinical trial stage in
The results announcement shows that as of the end of 2023, CMS has approximately 4,400 professional academic promotional personnel, and its promotion network has covered over 50,000 hospitals and medical institutions across
Accelerating international business development, forging new growth engines
Guided by the local unmet medical needs, CMS’s Southeast Asian business company "
In
The Share Award Schemes enhances employee enthusiasm and creativity, enabling long-term binding towards a shared future for all.
In order to maintain the momentum of innovation and accelerate the commercialization process of innovative products, on
According to the announcement, the schemes will determine "the stipulated performance targets" based on the overall financial performance of the Group, the cumulative sales revenue of a specified product or products, number of new products launched during any specified period. Among them, the "performance targets" associated with The First Batch of Share Awards include: launching 10 new products from 2020 to 2024. The cumulative total sales revenue of three blockbuster innovative drugs: METOJECT, VALTOCO, and VELPHORO in the three years from 2024 to 2026 will reach
In addition, the three independently operated business segments of "CMS Skinhealth", "CMS Vision" and "
By continuously improving the long-term incentive mechanism, CMS closely links employee interests with the Company's innovation development, maximizing employee enthusiasm to serve the Company's long-term development diligently and responsibly. Furthermore, the schemes releases sufficient confidence to the capital market for the CMS's steady development in the future.
Looking ahead, CMS will embrace “New CMS and New Era” after the short period of turbulence.
While accelerating its development under the guidance of innovation, CMS is firmly ushering in a new era. At the beginning of 2024, the term "innovative drugs" has been included in the government work report for the first time, indicating that innovative drugs have a leading strategic position among domestic emerging industries and have received great attention from the government. It will benefit pharmaceutical companies with advanced R&D capabilities, rich pipeline layouts, and mature commercialization systems.
CMS is diligent and devoted to innovation, and has always adhered to its mission of providing competitive products and services to meet unmet medical needs. With the gradual digestion of national VBP implementation impacts on its existing products, and the further deepening of its innovation development, CMS has been well-prepared for a brighter future going forward and will return to the track of sustained and healthy growth. Under its compliant and efficient commercialization system, the Company's innovative products and exclusive drugs will grow steadily. Concurrently, it is expected that more differentiated innovative products will be continuously launched with higher efficiency and more controllable costs every year in the future, continuously optimizing the Company's marketed product structure. As a mature pharmaceutical company with excellent historical performance, although the turbulence of adjustment period is inevitable, with the continuous enhancement of its innovation strength, CMS will surely usher in a new cycle of performance growth.
Media Contact
Brand:
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
Source:
Source:
2024 GlobeNewswire, Inc., source